{"id":389094,"date":"2023-12-26T00:00:00","date_gmt":"2023-12-26T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfmd0004-2023-biopharma-type-2-diabetes-disease-landscape-forecast-g7-2023\/"},"modified":"2026-03-31T10:31:22","modified_gmt":"2026-03-31T10:31:22","slug":"dlsfmd0004-2023-biopharma-type-2-diabetes-disease-landscape-forecast-g7-2023","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfmd0004-2023-biopharma-type-2-diabetes-disease-landscape-forecast-g7-2023\/","title":{"rendered":"Type 2 Diabetes | Disease Landscape &#038; Forecast | G7 | 2023"},"content":{"rendered":"<p>\u00a0<\/p>\n<p><!--{C}%3C!%2D%2D%5Bif%20!mso%5D%3E%3Cstyle%3E%0Av%5C%3A*%20%7Bbehavior%3Aurl(%23default%23VML)%3B%7D%0Ao%5C%3A*%20%7Bbehavior%3Aurl(%23default%23VML)%3B%7D%0Ab%5C%3A*%20%7Bbehavior%3Aurl(%23default%23VML)%3B%7D%0A.shape%20%7Bbehavior%3Aurl(%23default%23VML)%3B%7D%0A%3C%2Fstyle%3E%3C!%5Bendif%5D%2D%2D%3E--><!--{C}%3C!%2D%2D%5Bif%20!mso%5D%3E%3Cstyle%3E%0Av%5C%3A*%20%7Bbehavior%3Aurl(%23default%23VML)%3B%7D%0Ao%5C%3A*%20%7Bbehavior%3Aurl(%23default%23VML)%3B%7D%0Ab%5C%3A*%20%7Bbehavior%3Aurl(%23default%23VML)%3B%7D%0A.shape%20%7Bbehavior%3Aurl(%23default%23VML)%3B%7D%0A%3C%2Fstyle%3E%3C!%5Bendif%5D%2D%2D%3E--><\/p>\n<p>The type 2 diabetes (T2D) therapy market is forecast to expand through 2032, supported by polypharmacy and growing use of later-line therapies; however, loss of exclusivity for several key T2D brands like the dipeptidyl peptidase-IV (DPP-IV) inhibitors, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists will exert downward pressure on market sales. Nonetheless, the launch of Eli Lilly\u2019s first-in-class, glucose-dependent insulinotropic polypeptide (GIP) \/ GLP-1 receptor agonist, Mounjaro, and other late-phase emerging therapies will further support the T2D market through 2032. Although the marketed therapies help maintain HbA1c levels, there is a significant unmet need for disease-modifying therapies that can offer a better quality of life and reduce the treatment burden of intensive combination therapy.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul>\n<li>What are the drivers and constraints in the T2D market,\u00a0and how will the market evolve over the forecast period?<\/li>\n<li>How has the launch of Eli Lilly\u2019s tirzepatide (Mounjaro) affected the prescribing of GLP-1 receptor agonists such as Eli Lilly\u2019s Trulicity and Novo Nordisk\u2019s Ozempic in the United States? How will the therapy be received in the European market?<\/li>\n<li>How will the launch of nonbranded therapies affect the T2D market?<\/li>\n<li>What do key opinion leaders think about emerging therapies such as Novo Nordisk\u2019s insulin icodec and CagriSema?<\/li>\n<\/ul>\n<p><strong>Content highlights<\/strong><\/p>\n<p>Geographies: United States, EU5, Japan.<\/p>\n<p>Primary research: 19 country-specific interviews with thought-leading endocrinologists and diabetologists. Supported by survey data collected for this and other Clarivate research.<\/p>\n<p>Epidemiology: prevalence of T2D by country with population-specific diagnosed and drug-treatment rates.<\/p>\n<p>Forecast: 10-year, annualized, drug-level sales and patient share of key T2D therapies through 2032, segmented by brands \/ generics.<\/p>\n<p>Emerging therapies: Phase 3\/PR: 5 drugs; coverage of select preclinical, Phase 1, and Phase 2 products.<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast<\/em> provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Solution enhancement<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.<\/p>\n<p>Disease Landscape &#038; Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n<p>\u00a0<\/p>\n","protected":false},"template":"","class_list":["post-389094","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-type-1-diabetes","biopharma-therapy-areas-type-2-diabetes","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389094","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389094\/revisions"}],"predecessor-version":[{"id":575999,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389094\/revisions\/575999"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389094"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}